Previous 10 | Next 10 |
Shares of Agenus (NASDAQ: AGEN) , a clinical-stage biopharmaceutical company that specializes in immuno-oncology, saw its shares jump 18.4% on Thursday. The stock closed on Wednesday at $2.37, then opened on Thursday at $2.35, before rising to a high of $2.80 just before the market ...
Penny Stocks To Buy Or Avoid Completely? Trading penny stocks can be a very lucrative game if you know how to play it. But for most, excitement and emotion can take precedence over the right plan or strategy. That’s why, if you’re looking for top penny stocks to buy to...
LEXINGTON, Mass., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced it will host an in-person and virtual Research & Developme...
Clinical data in nine cancer indications from trial with 264 patients accrued Plenary discussion relating to expansion cohorts represent heavily pretreated patients Additional SITC presentations cover 1) botensilimab’s differentiated mechanism; 2) Phase 2 trial of anti-CD73...
Summary Agenus stock is way down post being edged out in PD1 therapy in 2021. The company recently started trials in colorectal cancer and melanoma. Agenus also has several clinical-stage drugs licensed to large-cap pharma companies. Agenus ( AGEN ) has been a bi...
Summary Today, we circle back on a small biotech concern called Agenus, Inc. for the first time in more than a year. The company has a half dozen collaboration deals with major players like Bristol-Myers Squibb and Gilead Sciences. Its vast pipeline has recently been re-priori...
Patricia Carlos named Chief Regulatory, Quality, and Safety Officer Todd Yancey, MD named Senior Global Clinical Development, Medical Affairs and Commercial Advisor LEXINGTON, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with an ext...
Phase 2 ACTIVATE trials to advance globally in metastatic patients who have progressed on available therapies Botensilimab, alone and in combination with balstilimab (PD-1), has demonstrated robust clinical activity in nine treatment-resistant tumor types, including microsatel...
Image source: The Motley Fool. Agenus (NASDAQ: AGEN) Q2 2022 Earnings Call Aug 09, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: Agenus (AGEN) Q2 2022 Earnings Call Transcript
Agenus Inc. (AGEN) Q2 2022 Earnings Conference Call August 09, 2022 08:30 AM ET Company Participants Ethan Lovell - Chief of External Affairs & Communications Officer Garo Armen - Chairman & Chief Executive Officer Christine Klaskin - Vice President-Finan...
News, Short Squeeze, Breakout and More Instantly...
Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its second quarter 2024 financial results before the market opens on Thursday, August 8, 2024. Agenus executives will host a co...
A look at the top 10 most actives in the United States Onconetix Inc. (ONCO) rose 46.5% to $0.2183 on volume of 404,016,812 shares NVIDIA Corporation (NVDA) rose 2.6% to $121.09 on volume of 317,123,916 shares PROSHARES TRUST (SQQQ) rose 1.5% to $8.23 on volume of 207,449,647 shares Max...
2024-07-18 12:11:22 ET Agenus Inc (NASDAQ: AGEN) faced a dramatic decline in its stock price on Thursday, plummeting more than 50%, following the US Food and Drug Administration (FDA’s) decision to advise against pursuing accelerated approval for its BOT/BAL colorectal cance...